Total Credits: .75 including .75 AOA Category 1-A Credit(s)
Learning Objectives:
Disclosure: Dr. Orenstein has no actual or potential conflict of interest in relation to this program or presentation.
Accreditation: This activity has been planned and implemented in accordance with the accreditation requirements and policies of the American Osteopathic Association (AOA). The Minnesota Osteopathic Medical Society (MOMS) is accredited by the American Osteopathic Association (AOA) to provide osteopathic continuing medical education for physicians.
Grievance Policy: Grievances regarding this program or AOA CME credit reporting will be handled on an individual basis. All grievances should be directed in writing to the MOMS Executive Director at info@mndo.org or by mail to Minnesota Osteopathic Medical Society, 1747 Beam Avenue, Suite 100, St. Paul, MN 55109-1128. Grievances that cannot be resolved by MOMS will then be sent to the AOA Council on CME, 142 East Ontario Street, Chicago, IL 60611.
| A Rational Approach to Therapy for COVID-19 (1.2 MB) | Available after Purchase | ||
Dr. Robert Orenstein is a professor of medicine and a senior fellow in the Academy of Educational Excellence at The Mayo Clinic College of Medicine and Science. He has been the Chair of the Division of Infectious Diseases at Mayo Clinic Arizona since 2012. He is board certified in infectious diseases, internal medicine and certified in Travel medicine and a fellow of the Infectious Diseases Society of America. He served as the Editor-in-Chief for the American Osteopathic Association from 2013-2020. Dr. Orenstein is an alumnus of the Des Moines University College of Osteopathic Medicine. He has received numerous awards for his educational efforts, including receiving the 2019 American Academy of Osteopathy’s, Academy Award, its highest service award for a non-member and the 2021 recipient of Mayo’s Above and Beyond Clinician Award.
Dr Orenstein practices infectious diseases at the Mayo Clinic Arizona, Phoenix campus where he sees complex inpatient and outpatient consultations in general and transplant infectious diseases. He is the founder of the Mayo Clinic Microbial Restoration Therapeutics Program and the C. difficile treatment program. He has played a leadership role in organizing Mayo’s response to both the COVID-19 and Monkeypox public health emergencies. He is currently leading a CDC/Arizona Department of Health Services sponsored Emerging Therapeutics Consortium focused on health equity and improving education on emerging infections across the state.
| 5 |
|
| 4 |
|
| 3 |
|
| 2 |
|
| 1 |
|